QTREX Quantum Ltd. clarified on July 22, 2026, that its recent filing of a resale registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) is not for a new issuance of ordinary shares or part of a new capital raise. The company emphasized that the filing was made solely to satisfy pre-existing contractual obligations regarding outstanding warrants issued pursuant to a securities purchase agreement dated February 5, 2026. QTREX stated that no proceeds will be received by the company in connection with the registration statement, except for proceeds which may be received upon the exercise of the ordinary share purchase warrants.

The company noted that it has since pivoted its business to Quantum Computing based on innovative Additively Manufactured Electronics (AME) technology purchased from Nano Dimension Ltd. As part of this transition, QTREX raised an additional $10 million USD in a deal consisting of common shares only at $1.5 per share with no warrants from a leading hedge fund. The registration statement does not constitute an active primary offering or the issuance of new securities by the company.

Business Focus

Following its acquisition of the AME platform, QTREX is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats. The company is advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. Additionally, QTREX continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

Registration Details

The filing is available via the SEC's EDGAR database, providing full regulatory disclosure regarding the resale. The prospectus serves as the primary document for potential investors to review the terms of the share offering.

QTREX Quantum Ltd. appointed Dr. Shlomit Chappel-Ram as an independent director effective July 14, 2026, strengthening its Board's technical expertise in Additively Manufactured Electronics (AME). The appointment comes as QTREX advances its AME platform from a validated capability into commercial component production for quantum computing infrastructure. Dr. Chappel-Ram brings direct operating experience in scaling complex hardware, aligning with QTREX's operational phase.

Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd., where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She co-authored peer-reviewed IEEE research on AME-fabricated, multi-metal-layer antenna architectures. Her background includes directing complex technology programs from early-stage development through regulatory approval and transfer to manufacturing.

Board Strengthening and Strategic Fit

The addition of Dr. Chappel-Ram to the Board is expected to enhance QTREX's ability to commercialize its AME technology. QTREX acquired the AME platform from Nano Dimension Ltd. in April 2026 and is applying it to high-density, thermally optimized quantum connectivity and proprietary, application-specific RF components. Dagi Ben-Noon, Chief Executive Officer of QTREX Quantum, emphasized that her deep technical understanding and proven track record in scaling complex hardware directly match the company's current operational needs.

Professional Background

Dr. Chappel-Ram has served as General Manager of Digma Medical since January 2025, overseeing operations, product development, regulatory and clinical programs, fundraising, and investor communications. From January 2021 to December 2024, she was Digma Medical's Vice President R&D and led Investor Relations activities. Her prior roles include senior R&D positions at Edwards Lifesciences (Cardioband) and Medinol Ltd. She also served as a consultant and advisory board member at Kidron Capital since April 2021 and at NGLi Holdings from March 2023 to March 2024.

Academic Credentials

Dr. Chappel-Ram holds a Ph.D. in Chemistry, summa cum laude, and an MBA from Bar-Ilan University. She completed postdoctoral work in Chemistry and Biochemistry at the City University of New York and finished the Directors and Senior Corporate Officeholders Program at Tel Aviv University’s LAHAV Executive Education.